It's unclear what the Bristol Myers Squibb deal with San Diego's Mirati Therapeutics means for the local workforce.
Mirati Therapeutics, a San Diego biotechnology company developing commercial drugs for cancer treatment, was just purchased by a pharmaceutical giant for more than $4.8 billion. Bristol Myers Squibb, one of the world’s largest pharmaceutical companies, announced Sunday evening that it will buy Mirati for $58 per share in a deal funded by cash and debt. There is potential for an additional $1 billion in milestone payments. The deal is expected to close in the first half of next year.
Mirati Therapeutics has been in San Diego developing treatments targeted at the genetic and immunological causes of cancer for 28 years. The biotech employed 593 people at the end of last year. In addition to Krazati, Bristol Myers Squibb gains access to Mirati’s pipeline of potential treatments for lung, bile duct and skin cancer tumors, as well as tumor mutations in pancreatic, lung and colorectal cancers.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Bristol-Myers Squibb to acquire Mirati in a $4.8 billion dealBristol-Myers Squibb to acquire Mirati in a $4.8 billion deal
Read more »
Bristol Myers Squibb to Acquire Mirati Therapeutics in Deal Worth Up to $5.8 BillionDeal expands pharmaceutical company’s portfolio of cancer drugs
Read more »
Bristol Myers Squibb to buy Mirati Therapeutics in deal worth up to $5.8 billionMirati develops commercial-stage oncology therapies, and through the deal, Bristol Myers Squibb will add lung-cancer medicine Krazati, among others, to its...
Read more »
Bristol-Myers Squibb to acquire Mirati in $5.8 billion dealBristol-Myers Squibb (BMY.N) on Sunday said it will acquire Mirati Therapeutics (MRTX.O) in a transaction that values the cancer drugmaker at up to $5.8 billion.
Read more »
Bristol-Myers Squibb shells out $5.8B for Mirati: 5 big deal reportsBristol-Myers Squibb shells out $5.8B for Mirati: 5 big deal reports
Read more »
Bristol Myers Squibb to buy cancer drugmaker Mirati Therapeutics in up to $5.8B dealBristol Myers Squibb will buy Mirati Therapeutics in a deal worth up to $5.8 billion, or $58 per share, the biopharmaceutical company announced Sunday.
Read more »